In vitro drug resistance and prognostic impact of p16INK4A/P15INK4B deletions in childhood T-cell acute lymphoblastic leukaemia

British Journal of Haematology

Volumn 112, Issue 3, 2001, Pages 680-690

  Ramakers van Woerden, N L ^a   Pieters, R ^b   Slater, R M ^c,d   Loonen, A H ^a   Beverloo, H B ^c   Van Drunen, E ^c   Heyman, M ^e   Calero Moreno, T ^e   Rots, M G ^a   Van Wering, E R ^f   Kamps, W A ^f,g   Janka Schaub, G E ^h   Veerman, A J P ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f Dutch Childhood Leukemia Study Group   (Netherlands)

^g UNIVERSITY OF GRONINGEN   (Netherlands)

^h NONE   (Germany)

Author keywords

Cellular drug resistance; Childhood acute lymphoblastic leukaemia; Gene deletions; p16 INK4a; p19ARF; Pl5 INK4b; T cell

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; METHOTREXATE; PREDNISOLONE; PROTEIN P15; PROTEIN P16;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HOMOZYGOTE; HUMAN; INFANT; LC 50; MAJOR CLINICAL STUDY; MALE; NEWBORN; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; T CELL LEUKEMIA;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE; FEMALE; GENE DELETION; GENES, P16; GLUCOCORTICOIDS; HOMOZYGOTE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; LEUKEMIA, T-CELL, ACUTE; MALE; PREDNISOLONE; RETROSPECTIVE STUDIES;

EID: 0035100030     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02586.x     Document Type: Article

References (70)

1. Detection of the Philadelphia chromosome in interphase nuclei
2. Frequent deletion in the methylthioadenosine phosphorylase gene in T-cell acute lymphoblastic leukemia strategies for enzyme-targeted therapy
3. Importance of pharmacodynamics in the in vitro antiproliferative activity of the antifolates methotrexate and 10-ethyl-10-deazaaminopterin against human head and neck squamous cell carcinoma
4. T cells from baxalpha transgenic mice show accelerated apoptosis in response to stimuli but do not show restored DNA damage-induced cell death in the absence of p53 gene product
5. Thymocyte apoptosis induced by p53-dependent and independent pathways
6. Clinical features and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation: A Pediatric Oncology Group Study
7. Deletions of interferon genes in acute lymphoblastic leukemia
8. Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia
9. ALL prognosis relapse: Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions
10. Immunologic and clinicopathologic features of common acute lymphoblastic leukemia antigen-positive childhood T-cell leukemia
11. A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies
12. Chromosome 9 short arm deletions in malignant diseases
13. Deletion of alpha-, beta-, and omega-interferon genes in malignant cells from children with acute lymphocytic leukemia
14. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features
15. Comparison of outcome, clinical, laboratory, and immunological features in 164 children and adults with T-ALL
16. Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia
17. Intensive therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features
18. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p151NK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias
19. Prognostic importance of p15INK4B and p16INK4 gene inactivation in childhood acute lymphocytic leukemia
20. Association of p19 (ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
21. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia
22. Alteration of CDKN2/p16 in human astrocytic tumors is related with increased susceptibility to antimetabolite anticancer agents
23. Randomized comparison of rotational chemotherapy in high-risk acute lymphoblastic leukaemia of childhood-follow up after 9 years
24. In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 treatment of childhood acute lymphoblastic leukemia: Two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97
25. A cell cycle regulator potentially involved in genesis of many tumor types
26. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
27. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: Results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-91)
28. In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood
29. Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay
30. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: Results of an in vitro study
31. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia
32. Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome
33. Fifty years of studies of the biology and therapy of childhood leukemia
34. The gene for familial polyposis coli maps to the long arm of chromosome 5
35. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents
36. p53 is required for radiation-induced apoptosis in mouse thymocytes
37. A novel p16INK4A transcript
38. Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia
39. Increase in radiation sensitivity of human malignant melanoma cells by expression of wild-type p16 gene
40. An additional breakpoint region in the BCL-1 locus associated with the t(11;14)(q13;q32) translocation of B-lymphocytic malignancy
41. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia
42. Frequent deletion of p16INK4a/MTS1 and p15INK4b/MTS2 in pediatric acute lymphoblastic leukemia
43. Mapping of the shortest region of overlap of deletions of the short arm of chromosome 9 associated with human neoplasia
44. Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia
45. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia
46. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia - Implications for treatment of infants
47. Acute lymphoblastic leukemia
48. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest
49. p16 gene homozygous deletions in acute lymphoblastic leukemia
50. Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I
51. Differential methotrexate resistance in childhood T- versus common/preB- acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay
52. Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia
53. Genetic studies of childhood acute lymphoblastic leukemia with emphasis on p16, MLL and ETV6 gene abnormalities - Results of St Jude total therapy study XII
54. Interphase cytogenetics of the t(8;21)(q22;q22) associated with acute myelogenous leukemia by two-color fluorescence in situ hybridization
55. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
56. Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01
57. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: Good initial steroid response allows early prediction of a favorable treatment outcome
58. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
59. p16INK4A participates in a G1 arrest checkpoint in response to DNA damage
60. Prognostic factors in childhood T-cell acute lymphoblastic leukemia: A Pediatric Oncology Group study
61. Complex structure and regulation of the p16 (MTS1) locus
62. Reversible, p16-mediated cell cycle arrest as protection from chemotherapy
63. Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood
64. P19 (ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2
65. Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: A Children's Cancer Group study
66. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia
67. p16 (INK4A) promotes differentiation and inhibits apoptosis of JKB acute lymphoblastic leukemia cells
68. Childhood acute lymphoblastic leukemia in the Netherlands - Randomized studies and nationwide treatment results from 1972 to 1995
69. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: A Pediatric Oncology Group study
70. Incidence and clinical significance of CDKN2/MTS1/p16ink4A and MTS2/P15ink4B gene deletions in childhood acute lymphoblastic leukemia